In vivo genetic screen identifies a SLC5A3-dependent myo-inositol auxotrophy in acute myeloid leukemia
暂无分享,去创建一个
W. McCombie | Sara Goodwin | Kenneth Chang | M. Figueroa | E. Hodges | M. Kramer | Ana S. H. Costa | C. Vakoc | O. Klingbeil | Zhaolin Yang | Yiliang Wei | Sofya A. Polyanskaya | Emmalee R Adelman | S. Iyer | O. E. Demerdash | K. Chang | Ana S. H. Costa | Maria E. Figueroa | Shruti V Iyer
[1] D. Sabatini,et al. CRISPR screens in physiologic medium reveal conditionally essential genes in human cells , 2020, bioRxiv.
[2] W. McCombie,et al. Abstract 1360: Understanding genetic variation in cancer using targeted nanopore long read sequencing , 2020 .
[3] M. Dong,et al. Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1‐p21/ZEB‐1 pathway , 2020, Journal of cellular and molecular medicine.
[4] F. Cheng,et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. , 2019, The Journal of clinical investigation.
[5] Kıvanç Birsoy,et al. Targeting extracellular nutrient dependencies of cancer cells , 2019, Molecular metabolism.
[6] K. Stegmaier,et al. Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo. , 2019, Blood.
[7] Aviad Tsherniak,et al. Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines , 2019, bioRxiv.
[8] M. Ferracin,et al. Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer , 2019, Cell reports.
[9] B. Garcia,et al. The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells. , 2019, Blood advances.
[10] F. Sedlazeck,et al. Targeted Nanopore Sequencing with Cas9 for studies of methylation, structural variants, and mutations , 2019, bioRxiv.
[11] D. Sabatini,et al. Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death , 2019, Nature.
[12] H. Dombret,et al. Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL , 2019, Clinical Cancer Research.
[13] Ligong Chen,et al. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development , 2018, Journal of molecular cell biology.
[14] J. Kinney,et al. A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence. , 2018, Cancer cell.
[15] Junwei Shi,et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma , 2018, eLife.
[16] J. Hou,et al. One-pot two-strain system based on glucaric acid biosensor for rapid screening of myo-inositol oxygenase mutations and glucaric acid production in recombinant cells. , 2018, Metabolic engineering.
[17] R. Hardison,et al. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells , 2018, Science.
[18] Peter W. Laird,et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.
[19] Heng Li,et al. Minimap2: pairwise alignment for nucleotide sequences , 2017, Bioinform..
[20] Francine E. Garrett-Bakelman,et al. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. , 2017, Cancer discovery.
[21] Ann E. Sizemore,et al. Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.
[22] Winston Timp,et al. Detecting DNA cytosine methylation using nanopore sequencing , 2017, Nature Methods.
[23] Michael D. Nyquist,et al. Harnessing Solute Carrier Transporters for Precision Oncology , 2017, Molecules.
[24] X. Bai,et al. Structural biology of solute carrier (SLC) membrane transport proteins , 2017, Molecular membrane biology.
[25] G. Georgiou,et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth , 2016, Nature Medicine.
[26] Thomas M. Norman,et al. A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response , 2016, Cell.
[27] C. Tanikawa,et al. Regulation of myo-inositol biosynthesis by p53-ISYNA1 pathway. , 2016, International journal of oncology.
[28] Navdeep S. Chandel,et al. Fundamentals of cancer metabolism , 2016, Science Advances.
[29] S. Ahuja,et al. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia , 2016, Journal of pharmacology & pharmacotherapeutics.
[30] Cunqi Ye,et al. Inositol Hexakisphosphate Kinase 1 (IP6K1) Regulates Inositol Synthesis in Mammalian Cells*♦ , 2016, The Journal of Biological Chemistry.
[31] A. Saiardi,et al. Phosphate, inositol and polyphosphates. , 2016, Biochemical Society transactions.
[32] D. Durocher,et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities , 2015, Cell.
[33] K. Giacomini,et al. SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.
[34] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[35] S. Schneider,et al. Inositol transport proteins , 2015, FEBS letters.
[36] Brian A. Joughin,et al. A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth , 2015, Genes & development.
[37] E. Gottlieb,et al. Analysis of Cell Metabolism Using LC-MS and Isotope Tracers. , 2015, Methods in enzymology.
[38] Jun S. Liu,et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens , 2014, Genome Biology.
[39] Kristala L J Prather,et al. Improving D-glucaric acid production from myo-inositol in E. coli by increasing MIOX stability and myo-inositol transport. , 2013, Metabolic engineering.
[40] C. Soulage,et al. Potential role and therapeutic interests of myo-inositol in metabolic diseases. , 2013, Biochimie.
[41] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[42] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[43] Pascale Anderle,et al. Solute carriers (SLCs) in cancer. , 2013, Molecular aspects of medicine.
[44] Y. Saunthararajah,et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. , 2013, Blood.
[45] L. Martiny,et al. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.
[46] J. Gribben,et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis , 2012, Cell Death and Disease.
[47] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[48] S. Rafii,et al. Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment. , 2011, Molecular cell.
[49] T. Nakanishi,et al. Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy. , 2011, Journal of pharmaceutical sciences.
[50] 이연수. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer , 2011 .
[51] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[52] J. McCubrey,et al. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients , 2010, Oncotarget.
[53] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[54] L. Nicholson,et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer , 2009, International journal of cancer.
[55] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[56] V. Ganapathy,et al. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. , 2009, Pharmacology & therapeutics.
[57] Anthony Mancuso,et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.
[58] M. Wunderlich,et al. Transforming human blood stem and progenitor cells: A new way forward in leukemia modeling , 2008, Cell cycle.
[59] D. Fennell,et al. In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion , 2006, Clinical Cancer Research.
[60] T. Kipps,et al. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.
[61] S. Chung,et al. Sodium/myo‐inositol cotransporter‐1 is essential for the development and function of the peripheral nerves , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] S. Roy,et al. Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein , 2004, Oncogene.
[63] D. Loo,et al. Kinetics and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus Oocytes , 2004, The Journal of Membrane Biology.
[64] J. Greer,et al. Loss of Murine Na+/myo-Inositol Cotransporter Leads to Brain myo-Inositol Depletion and Central Apnea* , 2003, The Journal of Biological Chemistry.
[65] E. O’Shea,et al. Regulation of Chromatin Remodeling by Inositol Polyphosphates , 2002, Science.
[66] D. Gagnon,et al. Identification of a Novel Na+/myo-Inositol Cotransporter* , 2002, The Journal of Biological Chemistry.
[67] J. Geiger,et al. The Crystal Structure and Mechanism of 1-l-myo-Inositol- 1-phosphate Synthase* , 2002, The Journal of Biological Chemistry.
[68] A. Massacrier,et al. New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families. , 2002, Gene.
[69] K. Shimamoto,et al. An enzymatic cycling method for the measurement of myo-inositol in biological samples. , 2001, Clinica chimica acta; international journal of clinical chemistry.
[70] J. Issa,et al. Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells , 2001, British Journal of Cancer.
[71] E. Ingulli,et al. Cd47 (Integrin-Associated Protein) Engagement of Dendritic Cell and Macrophage Counterreceptors Is Required to Prevent the Clearance of Donor Lymphohematopoietic Cells , 2001, The Journal of experimental medicine.
[72] J. Chatton,et al. Identification of a mammalian H+‐myo‐inositol symporter expressed predominantly in the brain , 2001, The EMBO journal.
[73] M. Schell,et al. Back in the water: the return of the inositol phosphates , 2001, Nature Reviews Molecular Cell Biology.
[74] C. Lagenaur,et al. Role of CD47 as a marker of self on red blood cells. , 2000, Science.
[75] E. Imai,et al. Effects of inhibition of myo-inositol transport on MDCK cells under hypertonic environment. , 1997, The American journal of physiology.
[76] N. Spinner,et al. The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. , 1995, Genomics.
[77] N. Tsukagoshi,et al. cDNA sequence for rkST1, a novel member of the sodium ion-dependent glucose cotransporter family. , 1994, Biochimica et biophysica acta.
[78] A. Yamauchi,et al. Cloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. , 1992, The Journal of biological chemistry.
[79] V. Bansal,et al. Phosphatidylinositol-derived precursors and signals. , 1990, Annual review of cell biology.
[80] Michael J. Berridge,et al. Inositol phosphates and cell signalling , 1989, Nature.
[81] R. Balaban,et al. Survey of osmolytes in renal cell lines. , 1988, The American journal of physiology.
[82] B. Holub. Metabolism and function of myo-inositol and inositol phospholipids. , 1986, Annual review of nutrition.
[83] R. Ramaley,et al. Purification and properties of Bacillus subtilis inositol dehydrogenase. , 1979, The Journal of biological chemistry.
[84] B. Kim,et al. L-asparaginase in the treatment of neoplastic diseases in children. , 1971, Cancer research.
[85] V. N. Finelli,et al. THE BIOSYNTHESIS OF FREE AND PHOSPHATIDE MYO-INOSITOL FROM GLUCOSE BY MAMMALIAN TISSUE SLICES. , 1963, The Journal of biological chemistry.
[86] F. Eisenberg,et al. Biosynthesis of inositol in rat testis homogenate , 1963 .